TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06884618: A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in

Sponsor: Hoffmann-La Roche · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 405 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$4,963,728

Rescue Site Savings

+$3,267,264

Unlock Full NCT06884618 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06884618 Rescue Dossier →